122 related articles for article (PubMed ID: 33194681)
1. Case Report: Primary and Acquired Resistance Mechanisms of Nimotuzumab in Advanced Esophageal Squamous Cell Carcinoma Revealed by Targeted Sequencing.
Sun D; Yan W; Zhu H; Liu Q; Hou H
Front Oncol; 2020; 10():574523. PubMed ID: 33194681
[TBL] [Abstract][Full Text] [Related]
2. The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.
Jia J; Cui Y; Lu M; Wang X; Li J; Li J; Li Y; Zhang X; Gao J; Zhou J; Lu Z; Gong J; Yu J; Sun Z; Liu C; Shen L; Zhang X
Clin Transl Oncol; 2016 Jun; 18(6):592-8. PubMed ID: 26459251
[TBL] [Abstract][Full Text] [Related]
3. Overall Survival of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Nimotuzumab in the Real World.
Saumell Y; Sanchez L; González S; Ortiz R; Medina E; Galán Y; Lage A
Adv Ther; 2017 Dec; 34(12):2638-2647. PubMed ID: 29134427
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and tolerability of nimotuzumab in unresectable, locally advanced/metastatic esophageal cancer: Indian hospital-based retrospective evidence.
Subramanian S; Sridharan N; Balasundaram V; Chaudhari S
South Asian J Cancer; 2019; 8(2):112-115. PubMed ID: 31069192
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma.
Sun D; Liu D; Liu Q; Hou H
Cancer Biol Ther; 2020 Dec; 21(12):1097-1104. PubMed ID: 33151119
[TBL] [Abstract][Full Text] [Related]
6. High EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients: preliminary clinical result and testable hypothesis.
Wang CY; Deng JY; Cai XW; Fu XL; Li Y; Zhou XY; Wu XH; Hu XC; Fan M; Xiang JQ; Zhang YW; Chen HQ; Perez R; Jiang GL; Zhao KL
Oncotarget; 2015 Jul; 6(21):18674-82. PubMed ID: 26124180
[TBL] [Abstract][Full Text] [Related]
7. Induction of PD-L1 expression by epidermal growth factor receptor-mediated signaling in esophageal squamous cell carcinoma.
Zhang W; Pang Q; Yan C; Wang Q; Yang J; Yu S; Liu X; Yuan Z; Wang P; Xiao Z
Onco Targets Ther; 2017; 10():763-771. PubMed ID: 28243112
[TBL] [Abstract][Full Text] [Related]
8. Combined nimotuzumab with chemoradiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma: A retrospective study.
Lai X; Gu Q; Zheng X; Liu G; Feng W; Lin X; Mao W
J Cancer Res Ther; 2016 Oct; 12(Supplement):89-95. PubMed ID: 27721263
[TBL] [Abstract][Full Text] [Related]
9. [Nimotuzumab Combined with Chemotherapy as Second- or Later-line
in the Treatment of Advanced Lung Squamous Cell Carcinoma].
Luo Y; Li J; Wang Y; Hao X; Qu F
Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):665-669. PubMed ID: 27760595
[TBL] [Abstract][Full Text] [Related]
10. Nimotuzumab abrogates acquired radioresistance of KYSE-150R esophageal cancer cells by inhibiting EGFR signaling and cellular DNA repair.
Liu H; Yang W; Gao H; Jiang T; Gu B; Dong Q; Xu W; Wu S; Sun X
Onco Targets Ther; 2015; 8():509-18. PubMed ID: 25750543
[TBL] [Abstract][Full Text] [Related]
11. Featured article: autophagic activation with nimotuzumab enhanced chemosensitivity and radiosensitivity of esophageal squamous cell carcinoma.
Song H; Pan B; Yi J; Chen L
Exp Biol Med (Maywood); 2014 May; 239(5):529-41. PubMed ID: 24625442
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
[TBL] [Abstract][Full Text] [Related]
13. A pilot study of nimotuzumab combined with cisplatin and 5-FU in patients with advanced esophageal squamous cell carcinoma.
Ling Y; Chen J; Tao M; Chu X; Zhang X
J Thorac Dis; 2012 Feb; 4(1):58-62. PubMed ID: 22295168
[TBL] [Abstract][Full Text] [Related]
14. RICTOR/mTORC2 affects tumorigenesis and therapeutic efficacy of mTOR inhibitors in esophageal squamous cell carcinoma.
Lu Z; Shi X; Gong F; Li S; Wang Y; Ren Y; Zhang M; Yu B; Li Y; Zhao W; Zhang J; Hou G
Acta Pharm Sin B; 2020 Jun; 10(6):1004-1019. PubMed ID: 32642408
[TBL] [Abstract][Full Text] [Related]
15. Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy.
Hirano H; Kato K
Jpn J Clin Oncol; 2019 May; 49(5):412-420. PubMed ID: 30920626
[TBL] [Abstract][Full Text] [Related]
16. Combined Nimotuzumab with Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma.
Thai Hoa NT; Quang Huy H
Cureus; 2020 May; 12(5):e8105. PubMed ID: 32426197
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and toxicity of nimotuzumab combined with radiotherapy in elderly patients with esophageal squamous cell carcinoma.
Guo JH; Chen MQ; Chen C; Lu HJ; Xu BH
Mol Clin Oncol; 2015 Sep; 3(5):1135-1138. PubMed ID: 26623065
[TBL] [Abstract][Full Text] [Related]
18. RICTOR expression in esophageal squamous cell carcinoma and its clinical significance.
Jiang WJ; Feng RX; Liu JT; Fan LL; Wang H; Sun GP
Med Oncol; 2017 Mar; 34(3):32. PubMed ID: 28132115
[TBL] [Abstract][Full Text] [Related]
19. Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma.
Park S; Shim JH; Lee B; Cho I; Park WY; Kim Y; Lee SH; Choi Y; Han J; Ahn JS; Ahn MJ; Park K; Sun JM
Lung Cancer; 2019 Aug; 134():7-15. PubMed ID: 31319998
[TBL] [Abstract][Full Text] [Related]
20. Correlation of epidermal growth factor receptor overexpression with increased epidermal growth factor receptor gene copy number in esophageal squamous cell carcinomas.
Yang YL; Xu KL; Zhou Y; Gao X; Chen LR
Chin Med J (Engl); 2012 Feb; 125(3):450-4. PubMed ID: 22490401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
